FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297008532> ?p ?o ?g. }

• W4297008532 endingPage "1596" @default.
• W4297008532 startingPage "1596" @default.
• W4297008532 abstract "In this study involving a cohort of employees of the National Airline company in Lebanon, we assessed humoral immunity levels and the effectiveness of two COVID-19 vaccines, Gam-COVID-Vac versus BNT162b2, after two doses and after a homologous and heterologous BNT162b2 booster, in addition to the impact of hybrid immunity. Vaccine effectiveness (VE) was retrospectively determined against laboratory-confirmed SARS-CoV-2 infection during the periods of Delta and Omicron variants' predominance, separately, and was calculated based on a case-control study design. The humoral immune response, measured by a SARS-CoV-2 anti-spike receptor-binding domain (RBD) IgG titer, was prospectively assessed after the aforementioned vaccination schemes at different time points. This study showed higher effectiveness of BNT162b2 after two doses (81%) compared to two doses of Gam-COVID-Vac (41.8%) against the Delta variant of SARS-CoV-2, which correlated with anti-spike antibody levels. Regarding the Omicron variant, protection against infection and antibody levels were severely compromised and the correlation between an anti-spike IgG titer and effectiveness was lost, unlike the situation during the Delta wave. Considering the booster vaccination schemes, a homologous BNT162b2 booster after a BNT162b2 primary vaccination induced a higher humoral immune response when compared to that induced by a heterologous BNT162b2 booster after a Gam-COVID-Vac primary vaccination. However, the VE of both booster regimens against the Omicron variant was almost equal (64% in the homologous regimen and 57% in heterologous regimen). Hybrid immunity evidenced a better humoral response and a greater and longer protection against Delta and Omicron infections compared to vaccination-induced immunity in COVID-19-naïve individuals. Finally, the findings show that VE waned with time during the same wave, highlighting the importance of reinforcing primary and booster COVID-19 vaccination mainly at the beginning of each wave during the surge of a new variant of concern." @default.
• W4297008532 created "2022-09-25" @default.
• W4297008532 creator A5018068105 @default.
• W4297008532 creator A5028211848 @default.
• W4297008532 creator A5039736678 @default.
• W4297008532 creator A5058406313 @default.
• W4297008532 creator A5061182011 @default.
• W4297008532 creator A5076378413 @default.
• W4297008532 date "2022-09-22" @default.
• W4297008532 modified "2023-09-25" @default.
• W4297008532 title "Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants" @default.
• W4297008532 cites W2804435636 @default.
• W4297008532 cites W3111255098 @default.
• W4297008532 cites W3165479483 @default.
• W4297008532 cites W3175995708 @default.
• W4297008532 cites W3177831450 @default.
• W4297008532 cites W3180389052 @default.
• W4297008532 cites W3180511106 @default.
• W4297008532 cites W3184226105 @default.
• W4297008532 cites W3186217635 @default.
• W4297008532 cites W3192494915 @default.
• W4297008532 cites W3194598131 @default.
• W4297008532 cites W3195399388 @default.
• W4297008532 cites W3196028820 @default.
• W4297008532 cites W3198831432 @default.
• W4297008532 cites W3204796311 @default.
• W4297008532 cites W3207354788 @default.
• W4297008532 cites W3211051404 @default.
• W4297008532 cites W3216544576 @default.
• W4297008532 cites W4200230275 @default.
• W4297008532 cites W4200560188 @default.
• W4297008532 cites W4205240144 @default.
• W4297008532 cites W4206040938 @default.
• W4297008532 cites W4206675538 @default.
• W4297008532 cites W4206997499 @default.
• W4297008532 cites W4210645820 @default.
• W4297008532 cites W4220678484 @default.
• W4297008532 cites W4220907252 @default.
• W4297008532 cites W4226229183 @default.
• W4297008532 cites W4226343533 @default.
• W4297008532 cites W4280503906 @default.
• W4297008532 cites W4280541635 @default.
• W4297008532 cites W4281634335 @default.
• W4297008532 cites W4281697576 @default.
• W4297008532 cites W4281766387 @default.
• W4297008532 cites W4282958946 @default.
• W4297008532 cites W4282967293 @default.
• W4297008532 cites W4283319609 @default.
• W4297008532 cites W4283758677 @default.
• W4297008532 cites W4283790352 @default.
• W4297008532 cites W4288492208 @default.
• W4297008532 cites W4293843074 @default.
• W4297008532 cites W4294549763 @default.
• W4297008532 cites W67693916 @default.
• W4297008532 doi "https://doi.org/10.3390/vaccines10101596" @default.
• W4297008532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36298460" @default.
• W4297008532 hasPublicationYear "2022" @default.
• W4297008532 type Work @default.
• W4297008532 citedByCount "1" @default.
• W4297008532 countsByYear W42970085322023 @default.
• W4297008532 crossrefType "journal-article" @default.
• W4297008532 hasAuthorship W4297008532A5018068105 @default.
• W4297008532 hasAuthorship W4297008532A5028211848 @default.
• W4297008532 hasAuthorship W4297008532A5039736678 @default.
• W4297008532 hasAuthorship W4297008532A5058406313 @default.
• W4297008532 hasAuthorship W4297008532A5061182011 @default.
• W4297008532 hasAuthorship W4297008532A5076378413 @default.
• W4297008532 hasBestOaLocation W42970085321 @default.
• W4297008532 hasConcept C104317684 @default.
• W4297008532 hasConcept C121332964 @default.
• W4297008532 hasConcept C12590561 @default.
• W4297008532 hasConcept C126322002 @default.
• W4297008532 hasConcept C1276947 @default.
• W4297008532 hasConcept C159047783 @default.
• W4297008532 hasConcept C159654299 @default.
• W4297008532 hasConcept C203014093 @default.
• W4297008532 hasConcept C203165030 @default.
• W4297008532 hasConcept C22070199 @default.
• W4297008532 hasConcept C2779134260 @default.
• W4297008532 hasConcept C2779341262 @default.
• W4297008532 hasConcept C2780115692 @default.
• W4297008532 hasConcept C2780868878 @default.
• W4297008532 hasConcept C2781413609 @default.
• W4297008532 hasConcept C3007834351 @default.
• W4297008532 hasConcept C3008058167 @default.
• W4297008532 hasConcept C32611913 @default.
• W4297008532 hasConcept C524204448 @default.
• W4297008532 hasConcept C54355233 @default.
• W4297008532 hasConcept C71924100 @default.
• W4297008532 hasConcept C86803240 @default.
• W4297008532 hasConcept C8891405 @default.
• W4297008532 hasConceptScore W4297008532C104317684 @default.
• W4297008532 hasConceptScore W4297008532C121332964 @default.
• W4297008532 hasConceptScore W4297008532C12590561 @default.
• W4297008532 hasConceptScore W4297008532C126322002 @default.
• W4297008532 hasConceptScore W4297008532C1276947 @default.
• W4297008532 hasConceptScore W4297008532C159047783 @default.
• W4297008532 hasConceptScore W4297008532C159654299 @default.

• next